# A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection

> **NCT04639466** · PHASE1,PHASE2 · COMPLETED · sponsor: **GeoVax, Inc.** · enrollment: 119 (actual)

## Conditions studied

- COVID-19 Infection

## Interventions

- **DRUG:** Placebo Administration
- **BIOLOGICAL:** Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1

## Key facts

- **NCT ID:** NCT04639466
- **Lead sponsor:** GeoVax, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-19
- **Primary completion:** 2025-10-31
- **Final completion:** 2025-12-03
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04639466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04639466, "A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04639466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*